** Shares of Sun Pharma SUN.NS , India's top drugmaker by
revenue, rise 3.6% to 1,420.85 rupees
** Stock second-biggest gainer on 20-member Nifty pharma
index .NIPHARM
** Analysts expect SUN's Q3 profit and rev to rise 12% and
9.5%, per LSEG, vs 5% rise in Q2 profit and ~11% Q2 rev growth
** SUN to see steady growth in FY23-26, led by uptick in
specialty products and domestic business - HSIE
** Likely launch of hair loss treatment drug Deuruxolitinib
in H2FY25 to add to specialty business' growth - Elara Capital
** Registration of Ilumya, drug for treating plaque
psoriasis, in China, will drive growth - Elara
** Analysts rate SUN, Cipla CIPL.NS at "buy", Dr Reddy's
REDY.NS rated "hold"- LSEG data
** CIPL, REDY beat quarterly profit estimates on strong U.S.
sales
** SUN's 26% rise in 2023 higher than CIPL's 16%, but short
of REDY's 37% climb
(Reporting by Kashish Tandon in Bengaluru)
((kashish.tandon@thomsonreuters.com))